



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

Mail Stop 4546

February 6, 2017

Michael M. Goldberg, M.D.  
President and Chief Executive Officer  
Navidea Biopharmaceuticals, Inc.  
5600 Blazer Parkway, Suite 200  
Dublin, Ohio 43017

**Re: Navidea Biopharmaceuticals, Inc.**  
**Preliminary Proxy Statement on Schedule 14A**  
**Filed December 5, 2016**  
**File No. 001-35076**

Dear Dr. Goldberg:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

/s/ Erin K. Jaskot, *for*

Suzanne Hayes  
Assistant Director  
Office of Healthcare and Insurance

cc: Kevin W. Waite, Esq.  
Moomjian, Waite & Coleman, LLP